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Background: Chronic obstructive pulmonary disease (COPD) is characterized by airflow
limitation caused by small airways increased resistance and/or terminal airspaces
emphysematous destruction. Spirometric detection of not fully reversible airflow
limitation unifies under the acronym COPD, a spectrum of heterogeneous conditions,
whose clinical presentations may be substantially different. In a cross-sectional study we
aimed to ascertain whether COPD phenotypes reflecting different mechanisms of airflow
limitation could be clinically identified.
Methods: Multidimensional scaling was used to visualize as a single point in a two-
dimension space the multidimensional variables derived from each of 322 COPD patients
(derivation set) by clinical, functional, and chest radiographic evaluation. Cluster analysis
assigned then a cluster membership to each patient data point. Finally, using cluster
membership as dependent variable and all data acquired as independent variables, we
developed multivariate models to prospectively classify another group of 93 COPD patients
(validation set) in whom high-resolution computerized tomography (HRCT) density
parameters were measured.
Results: A multivariate model based on nine variables acquired from the derivation set by
history (sputum characteristics), physical examination (adventitious sounds, hyperreso-
nance), FEV1/VC, and chest radiography (increased vascular markings, bronchial wall
thickening, increased lung volume, reduced lung density) partitioned the validation set
into two groups whose clinical, functional, chest radiographic, and HRCT characteristics
corresponded to either an airways obstructive or a parenchymal destructive COPD
phenotype.Elsevier Ltd. All rights reserved.
413183; fax: +39 055 4223202.
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M. Pistolesi et al.368Conclusion: Patients with COPD can be assigned a clinical phenotype reflecting the
prevalent mechanism of airflow limitation. The standardized identification of the
predominant phenotype may permit to clinically characterize COPD beyond its unifying
spirometric definition.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is character-
ized by expiratory airflow limitation caused by increased
resistance of the small airways and/or increased compliance
of the lung as a result of emphysema. The volume of air that
can be expired within 1 s after the beginning of a forced
expiration (FEV1) is the hallmark of COPD because it is
affected by inflammation and remodeling of the small
airways as well as by emphysematous destruction of the
terminal airspaces. Spirometric detection of not fully
reversible airflow limitation unifies under the acronym
COPD, a spectrum of heterogeneous conditions, whose
clinical presentations may be substantially different.
Forty years ago Burrows et al. described the distinctive
clinical, functional, radiological, and pathological charac-
teristics of the emphysematous and bronchial types of
chronic airways obstruction.1 The terms type A and type B
introduced to empirically differentiate COPD patients with
the emphysematous type from those with the bronchial type
of chronic airways obstruction1 are no longer in use because
a direct association between clinically defined types and
lung pathologic findings, such as centriacinar and panacinar
emphysema, has never been demonstrated.2 Coexistence in
the same patient of centriacinar and panacinar emphysema
was indeed often found.2
However, as it has recently emphasized,3–7 the current
tendency to lump a variety of conditions under the acronym
COPD may potentially blur important distinctions that could
be useful in clinical practice to improve the understanding
of the natural history of the disease and to focus treatment
strategies for different COPD phenotypes.
Aim of this research was to ascertain whether in a large
series of COPD patients it could be possible to identify
subgroups whose clinical, functional, and radiological
characteristics could enable to classify them as specific
phenotypic presentations.Methods
Subjects
From January 5 to December 31, 2004, we enrolled 415
consecutive COPD outpatients (83 females) with mild to
severe airflow limitation to derive clinical, functional, and
radiological characteristics that could represent the broad
spectrum of COPD presentations.8 Study enrollment was
based on stability of clinical conditions within 2 months,
availability of chest radiography within 1 week, and
patient’s willingness to participate. The institutional review
board approved the study. Informed consent was obtained
from all participants.Clinical evaluation
Patients were visited by six chest physicians who worked
independently on daily shift so as to cover 6 days a week.
Visit consisted in a thorough clinical history with adminis-
tration of the Medical Research Council questionnaire for
the assessment of dyspnea severity,9 physical examina-
tion,10–13 and evaluation of chest radiography (Table 1).
Physicians participating in the study had been previously
trained to detect the radiographic findings reported in Table
1 by a set of representative films.14,15 Table 1 was used as
reading table to standardize the interpretation. Interobser-
ver agreement in detecting the radiographic findings listed
in Table 1 was tested using the chest radiographs of the first
100 patients enrolled.
Pulmonary function studies
Static and dynamic lung volumes and single breath diffusing
capacity (DLCO) were measured by a mass-flow sensor (V6200
Autobox Body Plethysmograph; Sensor Medics, Yorba Linda,
CA) according to standard methodology.16,17 Arterial blood
gases were measured by a blood gas analyzer (ABL730;
Radiometer, Copenhagen, Denmark). For each patient, the
severity of COPD was graded according to the classification
of the Global Initiative for Chronic Obstructive Lung Disease
(GOLD).18
Spirometrically gated high-resolution computerized
tomography (HRTC)
Ninety-three among the 415 patients also underwent
spirometrically gated HRCT (Somatom Plus; Siemens, Erlan-
gen, Germany) to measure quantitative lung density para-
meters and served to prospectively validate the phenotype
classification process. There were no pre-established selec-
tion criteria to perform the HRCT study and to include these
patients in the validation set except for the clinician’s
perceived clinical utility of the examination to exclude
concomitant disease. HRCT was obtained at predefined
inspiratory lung volume to avoid the influence on density
measurements of different lung inflation levels during
scanning.19 Patients breathed through a spirometer (Micro-
medical Instruments, Rochester, UK) connected to the
scanner and performed reproducible vital capacity (VC)
maneuvers. Subsequently, the airflow through the spirom-
eter was interrupted at 90% of VC by a shutter triggering the
scanner to acquire images at three levels (carina, 5 cm
above, 5 cm below). Frequency histograms of lung attenua-
tion values of each section were averaged20 to derive X-ray
mean attenuation, as overall assessment of lung density, and
percentage area with X-ray attenuation values below 950
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Table 1 Variables derived from clinical history, physical examination, and chest radiography in 415 patients with COPD.
Clinical history Physical examination Chest radiography
Cough Cyanosis Increased vascular markings
Absent Pursued lips breathing  Vascular prominency
 Blurred margins
 Increased tortuosity
Occasional Neck veins dilatation
Chronic
Sputum















 Poorly defined micronodulation
 Lobular atelectasis






Very severe Reduced lung density
 Loss of normal background pattern
 Increased lucency
 Widening of peripheral clear zone
Increased lung volume
 Flattened emidiaphragms
 Increased retrosternal space
 Enlarged intercostal spaces
Bronchial wall thickening
 Wall thickening of perihilar bronchi seen
end-on or longitudinally
 Visibility of the wall of small bronchi
normally not seen
Variables derived from clinical history, physical examination and chest radiography were entered in the statistical analysis as 1
when present or 0 when absent. A radiographic variable was considered to be present when at least one of the related specific findings
was detected.
yDyspnea on effort has been scored into five categories according to the Medical Research Council (MRC) dyspnea scale. None: not
troubled by shortness of breath except with strenuous exercise; slight: troubled by shortness of breath when climbing a flight of stairs,
hurrying on the level or walking up a slight hill; moderate: walks slower than people of the same age on the level because of shortness
of breath; severe: stops for breath after walking about 100 yd or after a few minutes on the level; very severe: too breathless to leave
the house or breathless when dressing or undressing.
zParadoxical inspiratory indrawing of the lateral rib margin (due to direct traction by flattened diaphragm on the lateral rib margin).
yWheezes, crackles, ronchi.
Clinical phenotypes of COPD 369Hounsfield units (HU), as index of emphysema extent.21 The
HRCT study was then completed according to the clinical
needs of individual patients.Data analysis
This study was conducted according to the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) statement.22
To delve into our large dataset with an unbiased
approach, instead of using hypothesis-testing procedures
by classic statistical methods, as in logistic or discriminant
analysis, we explored the relationship among the whole setof variables by an undirected data driven approach. In
particular, to globally explore the dataset considering all
parameters at the same time we used the method called
multidimensional scaling.23 The analysis of multivariate data
is indeed rendered difficult from the inability to plot and
visualize the structure of multidimensional data. Multi-
dimensional scaling allows to represent multivariate data
points in a lower dimensional space allowing visual inspec-
tion of the whole dataset and to identify the presence
of subsets of aggregation in the whole set of categorical
(Table 1) and continuous (Table 2) variables derived from
322 of 415 patients (derivation set). All variables derived
from each patient were thus represented as a single data
point with two coordinates (principal coordinates I and II).
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Table 2 Anthropometric, smoking, functional, and HRCT densitometric characteristics of 415 patients with COPD.
Group of derivation of the classification
variables (derivation set) n ¼ 322, 66
females
Group of prospective validation
(validation set) n ¼ 93, 17 females
Mean (S.D.) Mean (S.D.) P
Age (year) 69 (7.7) 63 (8.0) o0.001
BMI 26.5 (4.6) 25 (4.1) NS
Pack/years 50 (30.8) 50 (37) NS
FVC% 85 (18) 85 (22) NS
FEV1% 62 (19) 53 (21) o0.001
FEV1/VC 52 (12) 43 (13) o0.001
FRC% 121 (30) 142 (33) o0.001
RV% 136 (39) 162 (49) o0.001
TLC% 105 (16) 116 (15) o0.001
DLCO% 72 (23) 70 (24) NS
pH 7.42 (0.03) 7.41 (0.02) NS
PaO2 (mmHg) 74 (9.3) 72 (9.0) NS
PaCO2 (mmHg) 40 (4.2) 40 (4.4) NS
PI (% lung area) – 22 (11) –
MLA (HU) – 880 (22) –
HRCT: high-resolution computerized tomography; %: percent of predicted value; HU: Hounsfield units; BMI: body mass index; pack/
years: number of daily cigarettes smoked x number of years of smoking/20; FVC: forced vital capacity; FEV1: forced expiratory volume
in the 1st second; VC: slow vital capacity; FEV1/VC: Tiffeneau index; FRC: functional residual capacity; RV: residual volume; TLC: total
lung capacity; DLCO: single-breath diffusing capacity for carbon monoxide; pH: negative logarithm of H
+ concentration; PaO2: O2 partial
arterial tension; PaCO2: CO2 partial arterial tension; PI (% lung area): relative lung area with attenuation values below 950HU for
scans at 90% of VC; MLA: mean computerized tomography lung attenuation for scans at 90% of VC.
M. Pistolesi et al.370Cluster analysis24 was then applied to segment the
whole set of data points into relatively homogeneous
subgroups. The clusters optimum number was selected
according to the average silhouette width (ASW) value,
a dimensionless number that must be higher than 0.25 to
define the presence of a reliable clustering structure in
the dataset.25 A clustering algorithm26 assigned to each
patient data point a membership in one of the identified
clusters.
A prospective classification model was subsequently
developed by multiple linear regression using all parameters
as independent variables and the patients cluster member-
ship as dependent variable. The model with the highest
discriminating power and the lowest number of variables,
selected by multiple analysis of variance27 in the 322
patients of the derivation set, was used to prospectively
classify the 93 patients of the validation set.
The classification obtained by applying the same model to
the whole sample of 415 patients was compared with GOLD
stages of COPD severity.
Interobserver agreement in detecting the radiographic
findings was assessed by k statistics. Student’s t-test,
Mann–Whitney test, and Fisher’s exact test were used
to compare continuous and categorical variables between
the different COPD subgroups identified. Data are reported
as mean7S.D. Significance was set at po0.05. Data
analysis and statistics were performed using GraphPad Prism
(version 3.02; San Diego, CA), S-Plus 2000 (Mathsoft,
Cambridge, MA), SPSS/PC WIN 11.5.1 (SPSS, Chicago, IL),
Mathcad (version 2001; Mathsoft), and C++ programming
language.Results
The anthropometric, smoking, and functional characteristics
of the 322 patients of the derivation set and of the 93
patients of the validation set included in the study are
reported in Table 2. Spirometrically gated HRCT densito-
metric measurements are reported for the 93 patients of
the validation set. The latter were significantly younger,
more obstructed, and hyperinflated with respect to the
322 patients from which the classification variables were
derived. Among the whole series of 415 patients 68 (16%)
were classified as GOLD 1 (mild COPD), 207 (50%) as GOLD 2
(moderate COPD), 113 (27%) as GOLD 3 (severe COPD), and
27 (7%) as GOLD 4 (very severe COPD). The validation set had
a significantly higher prevalence of patients that, according
to the GOLD classification, were staged as severe or very
severe COPD (51% of the patients in the validation set versus
29% of the patients in the derivation set).
Interobserver agreement in detecting the radiographic
findings of Table 1 ranged from moderate (k ¼ 0.59 for
interstitial changes) to very good (k ¼ 0.87 for increased
lung volume).
Figure 1 (left panel) shows the results of the application
of multidimensional scaling to the 322 patients included in
the derivation set. Visual inspection reveals the presence of
two partially overlapping subsets of aggregation. One subset
had negative values along principal coordinate I and higher
dispersion of data points with respect to a second subset
with positive values of principal coordinate I.
Figure 1 (right panel) shows the results of cluster analysis.
The highest value of ASW (ASW ¼ 0.32) was obtained when
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Figure 1 Left panel: two-dimensional graph obtained from the application of multidimensional scaling to the original
multidimensional set of heterogeneous parameters (categorical and continuous; listed in Tables 1 and 2) derived from 322 patients
with COPD. Each point of the graph represents the combination of all parameters (categorical and continuous) of each patient
defined by two coordinates (principal coordinate I and II). Right panel: partitioning in two clusters of the whole dataset. Each patient
data point is assigned a cluster membership (red or blue open circles) by a clustering algorithm.




Increased vascular markings 0.0938
Bronchial wall thickening 0.0566
Reduced lung density 0.1250
Adventitious breath sounds 0.0281
Chest hyperresonance 0.0596
FEV1/VC 0.0011
Increased lung volume 0.0529
Constant 0.5060
The model with the lowest number of variables and the
highest discriminating power to assign a cluster membership
to each of the 322 patient of the derivation set.
yFor the prospective classification of patients, the coeffi-
cients were multiplied by 0 or 1 according to the presence or
absence of the relative categorical variable. In the case of
FEV1/VC (ratio of forced expiratory volume in the first second
over slow vital capacity), the coefficient was multiplied for
the actual value of the continuous variable.
Clinical phenotypes of COPD 371considering two as the optimum number of clusters within
the series of patients data points. The two clusters
identified had only slight overlap.
The multiple regression model, developed by using as
independent variables all clinical, functional, and radio-
graphic data acquired in the 322 patients, defined the
previously determined cluster membership of the patients’
data points with great accuracy (R2 ¼ 0.92). The simplest
model, obtained by multiple analysis of variance (Table 3),
consisted of nine out of the original variables and accounted
for 91% of the variance in defining the cluster membership of
each patient (R2 ¼ 0.91). Among the selected variables four
were derived from history and physical examination, fourfrom chest radiography, and one from functional evaluation.
The selected variables were weighed by the relative
coefficient (Table 3) and linearly combined to obtain scores
for the classification of the 322 patients of the derivation set
and for the prospective classification of the 93 patients of
the validation set.
Figure 2 shows the bimodal shape of the probability
density curves of the classification scores of the 322 patients
used to develop the model and of the 93 patients used for
its prospective validation. Since the lowest value of the
probability density curve for the 93 patients of the
validation set was at a score of 0.56, this figure was used
as the cut-off value to subdivide these patients into two
subsets: patients with a score higher than 0.56 (Group A,
n ¼ 42, mean score7S.D. ¼ 0.6970.06) and patients with a
score equal or lower than 0.56 (Group B, n ¼ 51, mean
score7S.D.: 0.3870.09). Both groups had normally dis-
tributed classification scores and showed only marginal
overlap (Group B: mean score+2 S.D. ¼ 0.56; Group A: mean
score2 S.D. ¼ 0.57) with only 19 (20%) of the 93 patients
classified with scores comprised between 0.47 (Group B:
mean score+1 S.D.) and 0.63 (Group A: mean score1 S.D.).
The two subsets of the 93 patients differed significantly for
the vast majority of the categorical and continuous variables
considered in the study (Table 4).
The comparison between GOLD stages of COPD severity
and the distribution of the classification scores obtained in
the 415 patients by application of the multivariate regres-
sion model (Table 3) is reported in Figure 3. The box and
whisker plot (left panel) shows that patients with mild or
moderate COPD (GOLD 1 and 2) have significantly lower
(po0.001) classification scores than patients with severe or
very severe COPD (GOLD 3 and 4). The right panel in Figure 3
shows that, using the score cut-off value of 0.56 to subdivide
patients according to the predominant COPD phenotype,
patients staged as GOLD 1 and 2 have, indeed, a higher
probability (po0.001) than patients staged as GOLD 3 and 4
to be classified with the lower scores compatible with a
bronchial clinical phenotype. However, patients staged as
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Figure 2 Probability density curves of the classification scores obtained from the application of the multivariate regression model
reported in Table 3 to the 322 patients with COPD from whom the variables were derived (solid curve) and to the 93 patients used as a
validation set in whom the model was prospectively applied (dashed curve).
M. Pistolesi et al.372GOLD 3 and 4 had equal probability of being classified by the
multivariate regression model with scores compatible with
either COPD phenotype.Discussion
The main finding of this study is that a classification model
developed from unsupervised and prospectively validated
analysis can identify, along a continuous spectrum of clinical
presentations, two distinct phenotypes of patient with not
fully reversible chronic expiratory airflow limitation. The
subgroups specific findings identified by the objective
data driven analysis, although not specified in advance on
the basis of differences on which the subgroups were
expected to differ, do present definite biologically plausible
differences.
With respect to Group B, patients of Group A were mainly
characterized at clinical history by absent or occasional non-
productive cough; at physical examination they were
thinner, had more often pursued lips breathing, hypertro-
phied neck muscles, and chest inspiratory indrawing; the
chest wall digital percussion generated high intensity sounds
and at auscultation their breath sound was of low intensity.
At functional evaluation they showed more marked increase
in total lung capacity associated to a definite impairment of
lung diffusing capacity; indexes of expiratory airflow
limitation and hyperinflation were more severely altered.
They had chest radiographic evidence of increased lung
volume, reduced lung density, and attenuated vascular
markings resulting on HRCT as reduced mean lung attenua-
tion and increased percentage of lung area with density
values compatible with emphysema. In general, this
subgroup comprehends patients who present clinical, func-
tional, and radiological data concurring to characterizethem as being predominantly affected, to a various extent,
by an emphysematous clinical phenotype of COPD.
Group B patients were more often characterized by a
clinical history of chronic productive cough; they lacked
most physical signs displayed by Group A patients, and at
auscultation had more often adventitious breath sounds.
Their chest films showed increased bronchial and vascular
markings together with increased prevalence of interstitial
changes compatible with chronic lung inflammation result-
ing on HRCT as relatively higher values of mean lung
attenuation. On HRCT they also had a lower percentage of
lung area with density values compatible with emphysema.
In general, this subgroup comprehends patients who present
clinical, functional, and radiological findings concurring to
characterize them as being predominantly affected, to a
various extent, by a bronchial clinical phenotype of COPD.
Although each patient might present, along the contin-
uous bimodal spectrum of clinical presentations (Figure 2), a
particular pattern of combination of clinical, functional, and
radiological findings, one of the two clinical phenotypes was
usually predominant even in most patients with an inter-
mediate classification score. In the process of identifying the
predominant COPD phenotype, besides clinical and func-
tional data, a relevant role was played by conventional
chest radiography whose findings were confirmed by
spirometrically gated HRCT quantitative data.
Burrows et al. showed that a radiographic pattern of
peripheral vascular attenuation without associated chronic
inflammatory changes was highly correlated with the grade
of post-mortem anatomical emphysema.1 Besides chest
radiography, the Burrows’ study showed that the post-
mortem grade of anatomical emphysema was positively
predicted by reduced diffusing capacity and increased total
lung capacity, and negatively predicted by increased sputum
volume and increased PaCO2.
1 Physical examination was not
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Table 4 Variables significantly different in two subsets of 93 COPD patients (validation set) identified according to the scores
derived from the multivariate regression model.
Group A (n ¼ 42),
score40.56
Group B (n ¼ 51),
scorep0.56
Mean (S.D.) Mean (S.D.) P
Continuous variables
BMI 24 (3) 27 (4) o0.001
FEV1% 45 (19) 59 (21) o0.001
FEV1/VC 38 (12) 48 (12) o0.001
FRC% 158 (36) 129 (23) o0.001
RV% 184 (56) 145 (34) o0.001
TLC% 122 (16) 110 (12) o0.001
DLCO% 56 (24) 82 (17) o0.001
PI (% lung area) 30 (11) 16 (7) o0.001
MLA (HU) 893 (20) 874 (20) o0.001
Categorical variables Prevalence (%) Prevalence (%) Py
Absent cough 43 6 o0.001
Occasional cough 19 10 o0.001
Chronic cough 38 84 o0.001
Occasional sputum 62 10 o0.001
Chronic sputum 9 31 o0.001
Purulent sputum 29 59 o0.001
Pursued lips breathing 31 8 o0.01
Hypertrophy of accessory muscles 26 6 o0.001
Hoover’s sign 19 4 o0.05
Chest hyperresonance 81 33 o0.001
Reduced breath sounds 93 73 o0.05
Adventitious breath sounds 50 76 o0.01
Increased vascular markings 2 82 o0.001
Reduced vascular markings 79 16 o0.001
Interstitial changes 5 29 o0.005
Reduced lung density 95 29 o0.001
Increased lung volume 95 53 o0.001
Bronchial wall thickening 12 90 o0.001
See Table 2 for abbreviations.
Student’s t-test.
yFisher’s exact-test.
Clinical phenotypes of COPD 373considered. Apart from PaCO2, which did not show sig-
nificantly higher values in patients with a predominant
bronchial phenotype (Table 4), our study confirms the results
obtained by Burrows et al.1 The different relevance of PaCO2
in distinguishing the two phenotypes may be ascribed to
differences between our patients and those examined in the
Burrow’s study who had more severe conditions of respira-
tory insufficiency (mean PaCO2 ¼ 54mmHg, mean FEV1 ¼
0.67 l, FEV1/VC always lower than 50%).
There is increasing evidence that HRCT may provide
information in vivo on the pathologic changes occurring in
patients with COPD.28 The complexity and heterogeneity of
the pathological processes underlying COPD clinical pre-
sentation in primary care has been demonstrated in a large
series of patients studied by HRCT after an acute exacerba-
tion.29 Other studies in smaller series have shown that
among COPD patients those with emphysema documented
by HRCT had greater expiratory airflow limitation, hyperin-flation, and lower diffusing capacity.30,31 Furthermore, a
chest radiographic score of chronic inflammatory changes
showed a negative correlation with the HRCT score of
emphysema, suggesting that the features of conductive
airway inflammation are predominant in COPD patients with
no or with only trivial emphysema.30 Accordingly, O’Donnell
et al. found that sputum neutrophil counts in COPD was
closely associated with airway dysfunction, but not with the
severity of emphysema as assessed by HRCT and lung
diffusing capacity.32
The finding of an increased prevalence of a bronchial
phenotype among patients with mild and moderate disease,
as shown by the comparison between the distribution of
the classification scores and GOLD stages of COPD, is in
keeping with previous reports showing that patients with
an HRCT determined emphysema phenotype have more
severe clinical presentations of COPD.30,31 Although it is
difficult from the present cross-sectional study to exclude
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Figure 3 Left panel: box and whisker plot of the classification scores attributed by the multivariate regression model reported in
Table 3 to the whole sample of 415 COPD patients as a function of the GOLD stage of COPD severity. Line in box: 50th percentile
(median); limits of box: 25th and 75th percentiles; whiskers: minimum and maximum. No significant difference (Mann–Whitney test)
in the classification scores was found either between GOLD 1 and 2 stages or between GOLD 3 and 4 stages, while the classification
scores of GOLD 1 and 2 stages were significantly different (po0.001) from those of GOLD 3 and 4 stages. Right panel: histograms
representing the percent distribution, according to GOLD stages, of the 415 COPD patients classification scores above or below the
value of 0.56.
M. Pistolesi et al.374the effects of COPD progression on our findings, the
observed balanced prevalence of the two phenotypes
among patients with GOLD stages 3 and 4 may indicate that
disease progression does not wipe out the original clinical
phenotype.
Most HRCT studies in COPD have dealt with the severity
and extent of emphysema with little attention to the airway
changes. Recently, it has been shown that the combination
of a measure of airway thickening with the extent of
emphysema improved the estimate of pulmonary function
abnormalities and could be useful to differentiate COPD
patients with primarily parenchymal disease from those with
airway pathology.33–36 In the same line of evidence, COPD
patients with a clinical diagnosis of chronic bronchitis had on
HRCT increased bronchial wall thickness with respect to
COPD patients without clinical findings compatible with
chronic bronchitis.35 The latter, on the other hand, had on
HRCT a more severe reduction of X-ray mean lung attenua-
tion and a higher percentage of lung area with attenuation
values below 950HU, were more obstructed and hyperin-
flated, and had lower diffusing capacity.35 A correlation
between bronchial wall changes on HRCT and functional
indexes of obstruction was found only in patients with
clinical findings compatible with chronic bronchitis.35
Furthermore, it has been shown that COPD patients who
present airway wall thickening on HRCT have greater
reversibility of airflow obstruction in response to inhaled
bronchodilators and corticosteroids than those with emphy-
sema without bronchial wall thickening.36 These data, taken
together, suggest that expiratory airflow limitation is
mainly associated to airways pathology in COPD patients
with predominant features of chronic bronchitis, while
it is mainly associated to parenchymal destructive
changes in COPD patients with predominant features of
emphysema.
The series of patients from which, in this study, the
differentiating variables have been derived, could be
considered somewhat representative of the whole spectrum
of COPD clinical presentations, as it may be indicated by the
results of the prospective validation in a group of patientswith different age and COPD severity. On the other hand,
the different clinical characteristics of patients enrolled in
the validation set with respect to those of the derivation set
may have influenced the distribution of the classification
scores and, consequently, the determination of the cut-off
value used to subdivide the patients of the derivation set
into two subgroups (Figure 2). This study design limitation
could also have affected the observed distribution of
patients according to GOLD classification of COPD severity
(Figure 3). A further limitation of this work is that the cross-
sectional design of the study does not allow us to ascertain
whether patients with different phenotypes of COPD could
have different outcomes. It appears then that further
studies, possibly longitudinal and including greater samples
of patients, are needed to confirm the results obtained in
the present investigation.
In conclusion, it appears that each patient with COPD,
although being the individual clinical expression of a wide
and continuous spectrum of pathologic changes (different
lesions may coexist) causing expiratory airflow limitation,37
could be classified as being affected by predominant airway
disease or by predominant parenchymal destructive
changes. The identification of the predominant COPD
phenotype by few findings derived from clinical and
functional evaluation, as well as by standardized reading
of conventional chest radiography may offer the opportunity
to characterize this heterogeneous disease beyond its
unifying spirometric definition. This may well impact on
understanding the results of pharmacologic trials,38 on
clinician’s approach to patient treatment, and on deeper
knowledge of COPD natural history.Funding sources
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